Histogenics

News

US biotechs Ocugen and Histogenics have announced plans to merge, creating a specialist in drugs and gene therapies for ocular diseases.

News

Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.